Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Operating Margin (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Operating Margin readings, the most recent being 652.91% for Q1 2026.

  • On a quarterly basis, Operating Margin fell 69244.0% to 652.91% in Q1 2026 year-over-year; TTM through Mar 2026 was 152.56%, a 14585.0% decrease, with the full-year FY2025 number at 5.69%, up 7040.0% from a year prior.
  • Operating Margin hit 652.91% in Q1 2026 for Atara Biotherapeutics, up from 1978.31% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 39.53% in Q1 2025 to a low of 34180.54% in Q4 2022.
  • Median Operating Margin over the past 5 years was 383.56% (2024), compared with a mean of 3625.34%.
  • The widest YoY moves for Operating Margin: up 3295081bps in 2023, down -894325bps in 2023.
  • Atara Biotherapeutics' Operating Margin stood at 34180.54% in 2022, then soared by 96bps to 1229.74% in 2023, then skyrocketed by 97bps to 37.26% in 2024, then crashed by -5210bps to 1978.31% in 2025, then soared by 67bps to 652.91% in 2026.
  • The last three reported values for Operating Margin were 652.91% (Q1 2026), 1978.31% (Q4 2025), and 103.5% (Q3 2025) per Business Quant data.